"Tivic hits enrolment target for vagus nerve stimulation trial" was originally created and published by Medical Device ...

The resulting paper, “ Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain ...

STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...

An immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant in a Stanford ...

Trial details were in the study, “Percutaneous Tibial Nerve Stimulation’s Impact on Sexual Function in Female Patients with Neurogenic Detrusor Overactivity, Sexual Dysfunction, and Multiple Sclerosis ...

Utilizing the Dural Substitute Confetti technique during spinal cord stimulation trial implantation may reduce complications and shorten surgery time.

When pain signals are passed along the nervous system, proteins called calcium channels play a key role. Researchers at ...

Tivic Health Systems (Nasdaq:TIVC) announced today that it completed enrollment in a study for its vagus nerve stimulation (VNS) device.

Tivic Health has completed enrolment in a study being conducted to finetune its non-invasive vagus nerve stimulation (VNS) device that the company hopes to deploy in clinical indications not properly ...